Company Announcement / Press release Archives - Page 11 of 16

Number of shares and votes in Xspray

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of the exercise of warrants under the company's incentive programs. Through the exercise of warrants under the company's incentive program, the number of outstanding shares and votes has increased by 59,959 […]

Xspray announces positive stability data on HyNap-Dasa tablets

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces six months data from its stability study with HyNap-Dasa tablets manufactured in commercial scale. Six months stability data on commercially manufactured HyNap-Dasa demonstrates that the tablets complies with specifications and that they can be used in an upcoming ANDA filing. In February 2020 stability studies were initiated […]

Warrant holders exercise all warrants within the framework of incentive program

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the CEO Per Andersson and other warrant holders have chosen to make full use of the opportunity to subscribe for shares in Xspray by fully exercising their respective number of warrants in the warrant program LTIP 2017/2020. At the same time, Chairman of the Board Michael […]

Xspray strengthens the value of the product portfolio with patent protection for tablet of dasatinib propylene glycol solvate

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding its patent application for tablets containing dasatinib propylene glycol solvate (dasatinib PG). When issued this patent will significantly strengthen Xspray's IP rights and means that any possible future […]

Xspray announces preliminary results from the first study for its lead product candidate HyNap-Dasa

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces preliminary data from the first out of two bioequivalence studies in healthy volunteers with its lead product candidate HyNap-Dasa. The primary aim was to demonstrate bioequivalence for HyNap-Dasa compared to the reference product Sprycel. The first study did not fulfil statistical bioequivalence requirements due to high […]

Xspray enters manufacturing collaboration in Malta

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that Xspray has signed a term sheet with Pharmacare Premium Ltd. for a new manufacturing facility in Malta based on its patented technology platform. The new production lines will be placed within Pharmacare Premium’s existing facility. Apart from increasing Xspray’s manufacturing capacity for amorphous protein kinase inhibitors […]

Xspray Pharma publishes Interim Report Q2, January – June 2020

"We are in the final development phase of our first protein kinase inhibitor (PKI) project, HyNap-Dasa. HyNap- Dasa has shown good results in previous clinical studies and we are looking forward to seeing positive result this time as well. We have ahead of us an exciting and eventful second half of the year, with the […]

First study group has been dosed in Xspray Pharma’s ongoing pivotal registration studies with HyNap-Dasa

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that all healthy volunteers now have been dosed in the first of the two studies to demonstrate that HyNap-Dasa is bioequivalent to the original drug Sprycel® (dasatinib). The first group is conducted under fasting conditions and the second group is conducted under fed conditions. The two bioequivalence […]

Xspray – Virtual Capital Markets Day today at 14.00 CET

Xspray Pharma (Nasdaq Stockholm: XSPRAY) will host a virtual Capital Markets Day today, June 25, at 14.00-15:30 CET. Theme of the day will be how Xspray's product candidate HyNap-Dasa can pave the way for a number of followers based on the company's technology platform. Program (approximate time): 14:00 Xspray’s operations and remaining development steps for HyNap-Dasa– […]

Invitation to virtual Capital Markets Day with Xspray on June 25 at 14.00-15.30 CET

Xspray Pharma (Nasdaq Stockholm: XSPRAY) will host a virtual Capital Market Day on June 25 at 14.00-15.30 CET. Theme of the day will be how Xspray's product candidate HyNap-Dasa can pave the way for a number of followers based on the company's technology platform. The Capital Markets Day can be seen via Xspray's website: www.xspraypharma.com. […]